Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 16, 2008. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding share transactions rather than a financial performance report.
Material Changes
The filing details an increase in share interests for specific individuals following the re-investment of dividends paid on July 10, 2008. The transactions occurred at a price of £12.39 per share. The specific changes in holdings are:
- Mr E J Gray: 230.06 shares
- Mr D S Redfern: 182.00 shares
- Ms C Thomas: 113.75 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Points
- Verify the total shareholding positions of Mr E J Gray, Mr D S Redfern, and Ms C Thomas post-transaction.
- Confirm the dividend reinvestment plan terms applicable to the Deferred Investment Award Plan.
- Check the market price of GSK ordinary shares on July 10, 2008, to validate the £12.39 transaction price.